X4 Pharmaceuticals, Inc. XFOR NASDAQ

X4 Pharmaceuticals, Inc. (XFOR) generated $-15.53M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $0.00, free cash flow was $-15.53M.

Free cash flow margin was -604.6% of revenue. Cash conversion ratio was 0.65x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (50/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (10/100) — Cash conversion ratio was 0.65x suggests some earnings are non-cash items

Overall SharesGrow Score: 53/100 with 2/7 criteria passed.